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ABSTRACT
Background: Host- and pathogen-related factors asso-
ciated with septic shock in pneumococcal pneumonia are
not well defined. The aim of this study was to identify risk
factors for septic shock and to ascertain patient
outcomes. Serotypes, genotypes and antibiotic resistance
of isolated strains were also analysed.
Methods: Observational analysis of a prospective cohort
of non-severely immunosuppressed hospitalised adults
with pneumococcal pneumonia. Septic shock was defined
as a systolic blood pressure of ,90 mm Hg and
peripheral hypoperfusion with the need for vasopressors
for .4 h after fluid replacement.
Results: 1041 patients with pneumococcal pneumonia
diagnosed by Gram stain and culture of appropriate
samples and/or urine antigen test were documented, of
whom 114 (10.9%) had septic shock at admission. After
adjustment, independent risk factors for shock were
current tobacco smoking (OR, 2.11; 95% CI, 1.02 to 4.34;
p = 0.044), chronic corticosteroid treatment (OR, 4.45;
95% CI, 1.75 to 11.32; p = 0.002) and serotype 3 (OR,
2.24; 95% CI, 1.12 to 4.475; p = 0.022). No significant
differences were found in genotypes and rates of
antibiotic resistance. Compared with the remaining
patients, patients with septic shock required mechanical
ventilation more frequently (37% vs 4%; p,0.001) and
had longer length of stay (11 vs 8 days; p,0.001). The
early (10% vs 1%; p,0.001) and overall case fatality
rates (25% vs 5%; p,0.001) were higher in patients with
shock.
Conclusions: Septic shock is a frequent complication of
pneumococcal pneumonia and causes high morbidity and
mortality. Current tobacco smoking, chronic corticosteroid
treatment and infection caused by serotype 3 are
independent risk factors for this complication.
Streptococcus pneumoniae remains a major cause of
disease worldwide.1 Among pneumonia pathogens,
it is the most common cause of hospitalisation in
adults and the most frequent cause of death.2 3
Despite continuing improvements in aetiological
diagnosis, effective antibiotic treatment and
advances in supportive care, mortality rates in
patients with pneumococcal pneumonia remain
high, ranging from 5% to 35%.4
Septic shock at admission is one of the most
important factors influencing prognosis of patients
with pneumococcal pneumonia. It is known that
the intrinsic relationship between the host and the
microorganism is critical in the pathogenesis of
septic shock.5 Many host factors influence the
ability to develop an optimal immune response
against infection. Moreover, .90 serotypes of
pneumococci have been described, defined by
differences in the polysaccharide capsule,6 the
major virulence determinant of these organisms.7
Improvement in the knowledge of serotypes
associated with septic shock may help in the
design of new vaccines. However, within sero-
types, different genotypes may be identified8–11 and
these genotypes are associated with the presence of
different virulence determinants. The association
between infecting S pneumoniae genotype and
pneumonia severity has not been well established.
To date, little information is available regarding
the host- and pathogen-related factors associated
with pneumococcal pneumonia presenting with
septic shock. We performed this prospective study
to identify risk factors for septic shock and to
ascertain clinical outcomes in a large and homo-
geneous cohort of non-severely immunosuppressed
hospitalised adults with pneumococcal pneumo-
nia. Serotypes, genotypes and antibiotic resistance
of isolated strains were also analysed.
METHODS
Setting, patients and study design
The study was carried out in a 900-bed university
hospital for adults in Barcelona, Spain. The
hospital serves an area of 1 000 000 inhabitants
and admits ,24 000 patients per year. All non-
severely immunosuppressed adults admitted to the
hospital with pneumococcal pneumonia through
the emergency department from 13 February 1995
to 30 June 2008 were prospectively recruited and
followed-up. Patients with neutropenia, HIV infec-
tion and transplantation were not included.
For the purposes of this study patients were
divided into two groups: patients who presented
with septic shock at admission and those who did
not. (henceforth ‘‘pneumococcal pneumonia pre-
senting with shock’’ and ‘‘pneumococcal pneumo-
nia without shock’’
Clinical evaluation and follow-up
At the initial visit, before starting empirical
antibiotic treatment, patients underwent a com-
plete clinical history and physical examination.
Microbiological studies included two sets of blood
cultures and sputum Gram stain and culture when
available. Urinary antigen detection for S pneumo-
niae was performed if indicated by the attending
doctor. Patients were stratified into risk classes by
using the validated prediction rule calculated
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according to the Pneumonia Severity Index (PSI) scores, as
described elsewhere.12
Empirical antibiotic treatment was administered according to
hospital guidelines, which recommend the administration of a
b-lactam agent (ceftriaxone or amoxicillin–clavulanate) with or
without a macrolide or a fluoroquinolone. Combination
treatment was recommended for patients with clinical suspi-
cion of Legionella or an atypical pathogen or in the case of severe
pneumonia in the absence of a demonstrative sputum Gram
stain. Levofloxacin monotherapy was allowed for selected cases
(ie, patients with allergy to b-lactam agents and no prior
quinolone use).
Patients were seen daily during their hospital stay by one or
more of the investigators who provided medical advice when
requested and recorded clinical and microbiological data in a
computer-assisted protocol.
Definitions
Pneumococcal pneumonia was diagnosed in patients with signs
and symptoms of an acute-onset lower respiratory tract
infection, a new infiltrate on chest radiograph, one or more
cultures positive for S pneumoniae obtained from blood,
normally sterile fluids or sputum, and/or a positive test for
detection of urinary antigen. Only good quality samples of
sputum (,10 squamous epithelial cells and .25 leucocytes per
field) were accepted for processing.
The diagnosis of septic shock was based on a systolic blood
pressure of ,90 mm Hg and peripheral hypoperfusion with the
need for vasopressors for .4 h after fluid replacement at
admission. Current tobacco smoking was recorded when a
patient had smoked .10 cigarettes per day for at least 1 year
preceding the study, and alcohol consumption when a patient
had consumed .80 g of alcohol daily for at least 1 year
preceding the study. Chronic corticosteroid treatment was
defined as (20 mg/day of prednisone or its equivalent for a
period of at least 30 days; patients receiving higher doses were
excluded. A patient was considered to have been pneumococcal
vaccinated if 23-valent polysaccharide pneumococcal vaccine
had been administered in the 5 years before admission,
according to the hospital and primary healthcare centre records.
A patient was considered influenza vaccinated if influenza
vaccine had been administered during the year prior to
admission.
Early case fatality rate was defined as death due to any cause
(48 h after hospitalisation. Overall case fatality rate was
defined as death due to any cause during (30 days of
hospitalisation.
Microbiological studies
S pneumoniae was identified using standard microbiology
procedures. From 2000 onwards, urinary antigen detection
using a rapid immunochromatographic assay (Now, Binax,
Portland, Maine, USA) for S pneumoniae was also available.
Antimicrobial susceptibility was tested by microdilution
method, following the Clinical Laboratory Standard Institute
methods and criteria.13 14
Serotype was identified using the Quellung reaction at the
Spanish Reference Laboratory15 and/or by PCR following the
methodology described by the Centers for Disease Control
(CDC; http://www.cdc.gov/ncidod/biotech/strep/strepindex.
htm). Unusual serotype–genotype combinations were retested.
For molecular typing, all available strains were typed using
pulsed-field gel electrophoresis (PFGE) after restriction with
SmaI. PFGE patterns were compared with those of representa-
tive international pneumococcal clones of the Pneumococcal
Molecular Epidemiology Network.16 Sixty-six selected strains
representative of main clusters (at least one strain for each PFGE
pattern accounting for .2 pneumococci) were studied using
multilocus sequence typing, as described elsewhere.11 Allele
numbers and sequence types (STs) were assigned using the
pneumococcal multilocus sequence typing Web site.
Statistical analysis
To detect significant differences between groups, we used the x2
or Fisher exact test for categorical variables, and the Student t
test or the Mann–Whitney U test for continuous variables,
when appropriate. The multivariate analysis of factors poten-
tially associated with septic shock at admission included all the
significant variables in the univariate analysis with clinical
relevance. We used the stepwise logistic regression model of the
SPSS software package (SPSS, version 13.5; SPSS, Chicago,
Illinois, USA). Statistical significance was established at
a= 0.05. All reported p values are two tailed.
RESULTS
Over the study period, 1041 consecutive adults with pneumo-
coccal pneumonia were included, of whom 114 (10.9%) had
septic shock at admission. Table 1 details the microbiological
methods used to establish the diagnosis of pneumococcal
pneumonia.
Clinical features of the patients according to the study group
(pneumococcal pneumonia presenting with shock and pneu-
mococcal pneumonia without shock) are shown in table 2.
Patients with shock were significantly younger, were more
frequently current smokers, had more frequently received
chronic corticosteroid treatment and were less likely to have
received prior influenza vaccine than patients without shock.
They also had more frequent respiratory failure, multilobar
pneumonia and impaired consciousness at admission and were
more commonly classified into high-risk PSI classes than those
without.
Antibiotic-resistant pneumococci with a penicillin minimum
inhibitory concentration (MIC) >4 mg/ml (1.5% vs 1.7%; p = 1)
Table 1 Microbiological diagnosis of pneumococcal pneumonia
Pneumococcal
pneumonia
presenting with
shock
Pneumococcal
pneumonia without
shock
n = 114 (%) n = 927 (%)
One positive test 77 (67.5) 731 (78.8)
Gram stain and sputum culture 12 (10.5) 234 (25.2)
Blood cultures 15 (13.2) 109 (11.8)
Pleural fluid culture 4 (3.5) 36 (3.9)
Transthoracic needle aspiration
specimen culture
1 (0.9) 6 (0.6)
Urinary antigen test 45 (39.5) 346 (37.3)
More than one positive test 37 (32.5) 196 (21.1)
Gram stain and sputum culture,
blood cultures and urinary antigen
test
6 (5.3) 13 (1.4)
Gram stain and sputum culture,
and blood cultures
7 (6.1) 55 (5.9)
Blood cultures and urinary antigen
test
19 (16.7) 98 (10.6)
Gram stain and sputum culture,
and urinary antigen test
5 (4.4) 30 (3.2)
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and a cefotaxime MIC of 1 mg/ml (0% vs 1.9%; p = 0.617) were
distributed equally between groups. No differences in the rates
of resistance to erythromycin (11.8% vs 16.4%; p = 0.384),
chloramphenicol (1.4% vs 4.2%; p = 0.502), tetracycline (8.8%
vs 8.1%; p = 0.938) and cotrimoxazole (28.3% vs 28.5%;
p = 0.908) isolates were found between groups.
Five hundred and ninety-eight (92.0%) pneumococci were
available for serotyping and 474 (73.1%) for molecular typing.
The most frequent serotypes are summarised in table 3.
Serotype 3 was the most frequent serotype causing pneumo-
coccal pneumonia and was the most commonly associated with
septic shock. Conversely, serotype 1 was rarely associated with
this complication. The most common genotypes were ST2603
(22.6% vs 15.2%, respectively), Spain9V ST156 (7.5% vs 11.2%),
Netherlands3 ST180 (11.3% vs 7.8%), Netherlands7F ST191
(7.5% vs 4%) and Netherlands8 ST53 (9.4% vs 4.5%). Two
sequence types were found among serotype 3: the predominant
one was ST2603 and the second most predominant was ST180
(identifier of Netherlands3 ST180 PMEN clone). No significant
differences were found between the groups regarding genotypes.
The antibiotic treatment and clinical outcomes by study
groups are shown in table 4. No differences were found
regarding the median time to institution of initial antibiotic
treatment. Bacteraemia occurred more frequently in patients
with shock. This group also required mechanical ventilation
more frequently, and had longer length of hospital stay.
Moreover, the early and overall case fatality rates were higher
in patients who had septic shock at admission.
Table 5 summarises the results of the multivariate analysis of
factors potentially associated with septic shock. After adjust-
ment, independent risk factors were current tobacco smoking,
chronic corticosteroid treatment and infection caused by S
pneumoniae serotype 3. In a subanalysis of the 322 episodes of
bacteraemic pneumococcal pneumonia, the only independent
risk factor for septic shock was the use of chronic corticosteroid
treatment (OR 6.087, 95% CI 1.903 to 19.469).
DISCUSSION
This prospective study offers a comprehensive evaluation of the
host- and pathogen-related risk factors associated with septic
shock in pneumococcal pneumonia. We found that 10.9% of
patients had septic shock at admission, a figure similar to that
encountered in previous studies of community-acquired pneu-
monia, in which the incidence of septic shock ranged from 7.4%
to 10%.12 17
In our study, independent factors for septic shock were
current tobacco smoking, chronic corticosteroid treatment and
infection caused by S pneumoniae serotype 3. Neither infecting
genotype nor antibiotic resistance was found to be associated
with septic shock.
Tobacco smoking has been previously associated with
increased risk of infection,18–21 especially invasive pneumococcal
disease.2 22 It has been demonstrated that smoking negatively
affects the immune system, compromising the host’s ability to
mount an appropriate immune and inflammatory response.23–25
To our knowledge, our study is the first to link current tobacco
smoking directly with septic shock in pneumococcal pneumo-
nia. This finding provides additional support to encourage
patients at risk for pneumonia to undergo smoking cessation
programmes.
Glucocorticoids exert a decisive influence on the immune
function of macrophages and granulocytes, as well as in
systemic cytokine expression. Additionally, chronic corticoster-
oid treatment suppresses the production of corticotrophin-
releasing hormone and corticotrophin, and can induce adrenal
atrophy.26 Consequently, the adrenal responses to infection may
be insufficient to control the inflammatory situation. Although
evidence from randomised trials is lacking, treatment with
supplementary corticosteroids may be of benefit in patients
Table 2 Patients’ demographic and clinical characteristics
Characteristic
Pneumococcal
pneumonia
presenting with
shock (n = 114)
Pneumococcal
pneumonia
without shock
(n = 927)
p ValueNo. (%) No. (%)
Demographics
Median age (range) 64 (18–92) 70 (18–100) 0.003
Age >70 34 (29.8) 459 (49.5) ,0.001
Male, sex 67 (58.8) 618 (66.7) 0.093
Vaccination status
Influenza vaccine (season) 25 (21.9) 403 (43.5) 0.007
Pneumococcal vaccination 12 (10.5) 134 (14.5) 0.874
Current tobacco abuse 48 (42.1) 254 (27.4) 0.001
Heavy alcohol consumption 23 (20.2) 195 (21.0) 0.831
Underlying disease 84 (73.7) 742 (80.0) 0.109
COPD 33 (28.9) 271 (29.2) 1.00
Diabetes mellitus 21 (18.4) 187 (20.2) 0.711
Cancer 11 (9.6) 82 (8.8) 0.730
Cerebrovascular disease 6 (5.3) 49 (5.3) 1.00
Chronic heart disease 34 (29.8) 211 (22.8) 0.238
Chronic renal disease 7 (6.0) 55 (5.9) 0.836
Chronic liver disease 14 (12.3) 78 (8.4) 0.165
Dementia 2 (1.8) 28 (3.0) 0.764
Previous antibiotic treatment 17 (14.9) 166 (17.9) 0.786
Chronic corticosteroid treatment
( 20 mg/day)
14 (12.3) 55 (5.9) 0.015
Clinical characteristics at
admission
Median temperature (range) 37.5 (35.0–41.0) 38.0 (35.5–40.0) ,0.001
Median respiratory rate (range) 32 (11–55) 28 (12–50) ,0.001
Respiratory failure 84 (73.7) 538 (58.0) 0.002
Multilobar pneumonia 47 (41.2) 198 (21.4) ,0.001
Pleural effusion 27 (23.7) 194 (20.9) 0.746
Impaired consciousness 35 (30.7) 114 (12.3) ,0.001
High-risk pneumonia (PSI .90
points, classes IV and V)
91 (79.8) 552 (59.5) ,0.001
COPD, chronic obstructive pulmonary disease; PSI, Pneumonia Severity Index.
Table 3 Serotype distribution of 650 Streptococcus pneumoniae
isolates
Pneumococcal
pneumonia
presenting with
shock (n = 69)
Pneumococcal
pneumonia without
shock (n = 581)
p ValueNo. (%) No. (%)
Available serotype 65 (94.2) 533 (91.7) 0.475
3 25 (38.5) 127 (23.8) 0.010
8 5 (7.7) 26 (4.9) 0.367
7 5 (7.7) 22 (4.1) 0.200
19F 4 (6.2) 23 (4.3) 0.521
19A 4 (6.2) 22 (4.1) 0.512
4 4 (6.2) 25 (4.7) 0.543
1 1 (1.5) 53 (9.9) 0.025
14 3 (4.6) 28 (5.3) 1.00
9V 2 (3.1) 24 (4.5) 1.00
23F 1 (1.5) 13 (2.4) 1.00
Respiratory infection
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with pneumococcal pneumonia and septic shock in whom there
is evidence of adrenal insufficiency.
Serotype 3 is usually associated with adult pneumococcal
infection and is less frequent in children and in young adults. In
our study it caused nearly one in four of the cases of
pneumococcal pneumonia. Interestingly, we found that ser-
otype 3 was independently associated with septic shock.
Previous studies associated serotype 3 with a low invasive
potential but with higher mortality rates in bacteraemic
pneumococcal pneumonia.27–33 Probably, within serotype 3
isolates, the genetic background plays an important role in
virulence. In our study, two main genotypes were found among
serotype 3 strains (ST260 and ST180) and no significant
differences were observed among patients with or without
shock at presentation.
The 23-valent polysaccharide vaccine includes serotype 3 and
is recommended for use in adults in many countries. However,
vaccination rates among target persons remain low. The current
7-valent paediatric conjugate pneumococcal vaccine (PCV) lacks
serotype 3. It has been previously demonstrated that the
introduction of PCV7 has changed the serotypes causing
invasive pneumococcal disease in adults.1 Importantly, the
forthcoming 13-valent PCV includes this serotype and might
help to prevent septic shock in pneumococcal pneumonia.
Moreover, in the future the PCV13 vaccine will be available for
adult vaccination.
It is known that influenza virus alters the lungs in a way that
predisposes to adherence, invasion and induction of disease by
pneumococcus.34 It has been documented that prior influenza
vaccination prevents pneumonia hospitalisations and has a
substantial effect on all-cause mortality.34 In our study,
although influenza vaccination was found to be a protective
factor for septic shock in the univariate analysis, this finding did
not reach significance in the final model.
We found that patients presenting with septic shock required
mechanical ventilation more frequently and had a longer length
of hospital stay than patients without shock. As expected, these
patients had high early and overall case fatality rates. These
findings corroborate those of previous studies.12 35 36
Despite a number of strengths, our study has some
limitations that should be acknowledged. First, the possible
role of polymorphisms of innate immunity was not analysed.
Investigating the relationship between immune system genetics
and the severity of infection should therefore be a major focus
of future research. Secondly, the small number of cases of
pneumonia caused by some serotypes and genotypes precluded
analysing their potential correlation with shock. Thirdly, the
study was carried out in a single centre and the results might
not translate to other geographic areas.
In summary, septic shock is a frequent complication of
pneumococcal pneumonia and causes high morbidity and
mortality. Current tobacco smoking, chronic corticosteroid
treatment and infection caused by S pneumoniae serotype 3 are
independent risk factors for this serious complication.
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